Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia

ClinicalTrials.gov ID: NCT00793819

Public ClinicalTrials.gov record NCT00793819. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled Phase 2 Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia

Study identification

NCT ID
NCT00793819
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Watson Pharmaceuticals
Industry
Enrollment
215 participants

Conditions and interventions

Interventions

  • silodosin Drug

Drug

Eligibility (public fields only)

Age range
50 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2008
Primary completion
Sep 30, 2009
Completion
Sep 30, 2009
Last update posted
Mar 8, 2012

2009

United States locations

U.S. sites
27
U.S. states
20
U.S. cities
27
Facility City State ZIP Site status
Watson Investigational Site Huntsville Alabama
Watson Investigational Site Laguna Hills California
Watson Investigational Site San Diego California
Watson Investigational Site Aventura Florida
Watson Investigational Site Clearwater Florida
Watson Investigational Site Orlando Florida
Watson Investigational Site Marietta Georgia
Watson Investigational Site Sandy Springs Georgia
Watson Investigational Site Coeur d'Alene Idaho
Watson Investigational Site West Des Moines Iowa
Watson Investigational Site Paducah Kentucky
Watson Investigational Site Greenbelt Maryland
Watson Investigational Site Troy Michigan
Watson Investigational Site Missoula Montana
Watson Investigational Site Omaha Nebraska
Watson Investigational Site Las Vegas Nevada
Watson Investigational Site Lawrenceville New Jersey
Watson Investigational Site Albuquerque New Mexico
Watson Investigational Site Bay Shore New York
Watson Investigational Site New York New York
Watson Investigational Site Williamsville New York
Watson Investigational Site Concord North Carolina
Watson Investigational Site Salisbury North Carolina
Watson Investigational Site Bethany Oklahoma
Watson Investigational Site Bala-Cynwyd Pennsylvania
Watson Investigational Site Myrtle Beach South Carolina
Watson Investigational Site Burien Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00793819, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 8, 2012 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00793819 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →